Compare MANU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MANU | IDYA |
|---|---|---|
| Founded | 1878 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2012 | 2019 |
| Metric | MANU | IDYA |
|---|---|---|
| Price | $15.31 | $34.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $23.00 | ★ $49.42 |
| AVG Volume (30 Days) | 445.6K | ★ 908.2K |
| Earning Date | 12-11-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $892,268,193.00 | $214,834,000.00 |
| Revenue This Year | $0.16 | $2,434.86 |
| Revenue Next Year | $15.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.48 | ★ 5377.66 |
| 52 Week Low | $12.05 | $13.45 |
| 52 Week High | $19.65 | $37.08 |
| Indicator | MANU | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 53.39 |
| Support Level | $14.90 | $33.10 |
| Resistance Level | $16.11 | $34.45 |
| Average True Range (ATR) | 0.46 | 1.39 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 41.34 | 21.98 |
Manchester United PLC operates as a professional football club with related activities, generating revenue prominently through commercial, broadcasting, and matchday segments. The commercial segment monetizes the various brands via sponsorships, retail, merchandising, apparel, and product licensing. Broadcasting revenue comes from television rights linked to football leagues and competitions, alongside content delivered through its dedicated TV channel all over the globe. Matchday income includes ticket sales, hospitality, merchandise, and services at its stadium. Manchester United is based in England. The company's operations and fan base extends to many countries, supporting a diversified revenue model based on brand engagement and football-related content.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.